The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

Zydus Lifesciences gains FDA tentative approval for generic ibrutinib, enhancing access to vital cancer treatment for ...

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for ...

A multicenter study evaluating lurbinectedin in patients with extensive-stage small cell lung cancer who received second-line ...

Panelists discuss how biomarker development in anal cancer remains limited with PD-L1 status not influencing treatment ...

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, ...

Panelists discuss how implementing combination immunotherapy in clinical practice faces institutional barriers, including ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

New findings confirm that partial-breast and reduced-dose radiotherapy effectively treat low-risk early-stage breast cancer ...

An expert discusses that while CAR T-cell therapy has transformed the treatment landscape for primary refractory diffuse ...